Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.

Souza M, Al-Sharif L, Antunes VLJ, Huang DQ, Loomba R

Hepatology (Baltimore, Md.)4 Feb 2025Cited by 86 (Europe PMC)

PMID39903735PMCIDPMC12614381DOI10.1097/hep.0000000000001254PepBankPUB-39903735

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanSystematic reviewEfficacy outcome
In a network meta-analysis of randomized trials in biopsy-proven MASH, survodutide was significantly better than placebo for fibrosis improvement without worsening of MASH.
In plain wordsIn a pooled analysis of trials in people with MASH, survodutide improved liver scarring more often than placebo.
Peptide
Survodutide
Outcome
IncreaseFibrosis improvement of at least 1 stage without MASH worsening
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
Pegozafermin, cilofexor + firsocostat, denifanstat, survodutide, obeticholic acid, tirzepatide, resmetirom, and semaglutide were significantly better than placebo in achieving fibrosis regression without worsening MASH.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed and Embase databases from January 1, 2020 to December 1, 2024, for published randomized controlled trials comparing pharmacological interventions in patients with biopsy-proven MASH.
Summary · context
A total of 29 randomized controlled trials (n=9324) were included.
Report a problemFND-3990373501
02HumanSystematic reviewEfficacy outcome
In a network meta-analysis of randomized trials in biopsy-proven MASH, survodutide was significantly better than placebo for MASH resolution without worsening of fibrosis.
In plain wordsIn a pooled analysis of trials in people with MASH, survodutide resolved MASH more often than placebo.
Peptide
Survodutide
Outcome
IncreaseMASH resolution without worsening fibrosis
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
Pegozafermin, survodutide, tirzepatide, efruxifermin, liraglutide, vitamin E + pioglitazone, resmetirom, semaglutide, pioglitazone, denifanstat, semaglutide, and lanifibranor were significantly better than placebo in achieving MASH resolution without worsening fibrosis.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed and Embase databases from January 1, 2020 to December 1, 2024, for published randomized controlled trials comparing pharmacological interventions in patients with biopsy-proven MASH.
Summary · context
A total of 29 randomized controlled trials (n=9324) were included.
Report a problemFND-3990373502
03HumanSystematic reviewEfficacy outcome
In the network meta-analysis, survodutide ranked second most effective for MASH resolution without worsening fibrosis (SUCRA 90.87), after pegozafermin.
In plain wordsIn a pooled analysis of MASH trials, survodutide ranked second among the drugs compared for resolving MASH.
Peptide
Survodutide
Outcome
IncreaseSUCRA rank for MASH resolution without worsening fibrosis
Study
n: not reported in source
Comparator
Other pharmacological agents (rank order)
Analysis
Primary
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Measurements
SUCRA
90.87
survodutide, MASH resolution
Source sentences
Summary
Pegozafermin (SUCRA: 91.75), survodutide (SUCRA: 90.87), and tirzepatide (SUCRA: 84.70) were ranked the most effective interventions for achieving MASH resolution without worsening fibrosis.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed and Embase databases from January 1, 2020 to December 1, 2024, for published randomized controlled trials comparing pharmacological interventions in patients with biopsy-proven MASH.
Summary · context
A total of 29 randomized controlled trials (n=9324) were included.
Report a problemFND-3990373503
04HumanSystematic reviewEfficacy outcome
In patients with biopsy-proven MASH, tirzepatide was significantly better than placebo for fibrosis regression without worsening MASH.
In plain wordsIn patients with MASH, tirzepatide was better than placebo at reducing liver scarring without making the disease worse.
Peptide
Tirzepatide
Outcome
IncreaseFibrosis improvement without MASH worsening
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
Pegozafermin, cilofexor + firsocostat, denifanstat, survodutide, obeticholic acid, tirzepatide, resmetirom, and semaglutide were significantly better than placebo in achieving fibrosis regression without worsening MASH.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed and Embase databases from January 1, 2020 to December 1, 2024, for published randomized controlled trials comparing pharmacological interventions in patients with biopsy-proven MASH.
Summary · context
A total of 29 randomized controlled trials (n=9324) were included.
Report a problemFND-3990373504
05HumanSystematic reviewEfficacy outcome
In patients with biopsy-proven MASH, semaglutide was significantly better than placebo for fibrosis regression without worsening MASH.
In plain wordsIn patients with MASH, semaglutide was better than placebo at reducing liver scarring without making the disease worse.
Peptide
Semaglutide
Outcome
IncreaseFibrosis improvement without MASH worsening
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
Pegozafermin, cilofexor + firsocostat, denifanstat, survodutide, obeticholic acid, tirzepatide, resmetirom, and semaglutide were significantly better than placebo in achieving fibrosis regression without worsening MASH.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed and Embase databases from January 1, 2020 to December 1, 2024, for published randomized controlled trials comparing pharmacological interventions in patients with biopsy-proven MASH.
Summary · context
A total of 29 randomized controlled trials (n=9324) were included.
Report a problemFND-3990373505
06HumanSystematic reviewEfficacy outcome
In patients with biopsy-proven MASH, tirzepatide was significantly better than placebo for MASH resolution without worsening fibrosis.
In plain wordsIn patients with MASH, tirzepatide was better than placebo at resolving the disease without worsening liver scarring.
Peptide
Tirzepatide
Outcome
IncreaseMASH resolution without worsening fibrosis
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
Pegozafermin, survodutide, tirzepatide, efruxifermin, liraglutide, vitamin E + pioglitazone, resmetirom, semaglutide, pioglitazone, denifanstat, semaglutide, and lanifibranor were significantly better than placebo in achieving MASH resolution without worsening fibrosis.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed and Embase databases from January 1, 2020 to December 1, 2024, for published randomized controlled trials comparing pharmacological interventions in patients with biopsy-proven MASH.
Summary · context
A total of 29 randomized controlled trials (n=9324) were included.
Report a problemFND-3990373506
07HumanSystematic reviewEfficacy outcome
In patients with biopsy-proven MASH, liraglutide was significantly better than placebo for MASH resolution without worsening fibrosis.
In plain wordsIn patients with MASH, liraglutide was better than placebo at resolving the disease without worsening liver scarring.
Peptide
Liraglutide
Outcome
IncreaseMASH resolution without worsening fibrosis
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
Pegozafermin, survodutide, tirzepatide, efruxifermin, liraglutide, vitamin E + pioglitazone, resmetirom, semaglutide, pioglitazone, denifanstat, semaglutide, and lanifibranor were significantly better than placebo in achieving MASH resolution without worsening fibrosis.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed and Embase databases from January 1, 2020 to December 1, 2024, for published randomized controlled trials comparing pharmacological interventions in patients with biopsy-proven MASH.
Summary · context
A total of 29 randomized controlled trials (n=9324) were included.
Report a problemFND-3990373507
08HumanSystematic reviewEfficacy outcome
In patients with biopsy-proven MASH, semaglutide was significantly better than placebo for MASH resolution without worsening fibrosis.
In plain wordsIn patients with MASH, semaglutide was better than placebo at resolving the disease without worsening liver scarring.
Peptide
Semaglutide
Outcome
IncreaseMASH resolution without worsening fibrosis
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
Pegozafermin, survodutide, tirzepatide, efruxifermin, liraglutide, vitamin E + pioglitazone, resmetirom, semaglutide, pioglitazone, denifanstat, semaglutide, and lanifibranor were significantly better than placebo in achieving MASH resolution without worsening fibrosis.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed and Embase databases from January 1, 2020 to December 1, 2024, for published randomized controlled trials comparing pharmacological interventions in patients with biopsy-proven MASH.
Summary · context
A total of 29 randomized controlled trials (n=9324) were included.
Report a problemFND-3990373508
09HumanSystematic reviewEfficacy outcome
In the network meta-analysis, tirzepatide (SUCRA 84.70) was ranked among the three most effective interventions for MASH resolution without worsening fibrosis.
In plain wordsIn the network meta-analysis, tirzepatide ranked among the three best treatments for resolving MASH without worsening liver scarring.
Peptide
Tirzepatide
Outcome
Not applicableSUCRA rank for MASH resolution
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Measurements
SUCRA
84.7
MASH resolution
Source sentences
Summary
Pegozafermin (SUCRA: 91.75), survodutide (SUCRA: 90.87), and tirzepatide (SUCRA: 84.70) were ranked the most effective interventions for achieving MASH resolution without worsening fibrosis.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed and Embase databases from January 1, 2020 to December 1, 2024, for published randomized controlled trials comparing pharmacological interventions in patients with biopsy-proven MASH.
Summary · context
A total of 29 randomized controlled trials (n=9324) were included.
Report a problemFND-3990373509

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 5 to 40Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 19:08 UTC. The status did not change between them.
Study results updated
Versions 2 to 4
9 Oct 2026, 03:07 UTC
The same notice was added 3 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.

Summary

Results from this study9

Version history

Subjects

Publication types

MeSH terms

Keywords